RATIONALE: Granulomatous-lymphocytic interstitial lung disease (GLILD) has emerged as a major cause of morbidity in patients with common variable immunodeficiency (CVID). While GLILD is among the most serious noninfectious pulmonary complications of CVID, risk factors for this condition have not been reported. OBJECTIVES: To identify clinical, physiologic, and serologic risk factors for GLILD in adults with CVID. METHODS: Of 345 consecutive adult patients with CVID, we identified 34 in the National Jewish Health research database who had a radiographic-pathologic diagnosis of GLILD evaluated between 2002 and 2014. Each case was age and sex matched to 52 CVID control subjects. We used logistic regression to determine independent predictors of GLILD. A mixed effects model was used to estimate the longitudinal change in percent predicted FVC. MEASUREMENTS AND MAIN RESULTS: The mean time from CVID diagnosis to GLILD detection was 7.8 years. Compared with matched control subjects, cases were more likely to have a history of autoimmune cytopenia, hypersplenism, polyarthritis, lower marginal zone and switched memory B cells, and restrictive lung function. Multivariate analysis revealed that hypersplenism (odds ratio [OR], 24; 95% confidence interval [CI], 4.5-179.1), polyarthritis (OR, 19; 95% CI, 2.3-206.8), and percent predicted FVC (OR, 0.93; 95% CI, 0.87-0.98) were independently associated with the development of GLILD. The rate of change of percent predicted FVC (slope, P = 0.48) did not vary significantly in patients with GLILD over a mean follow-up of 7 years after diagnosis. CONCLUSIONS: Hypersplenism and polyarthritis are strong risk factors for GLILD in patients with CVID. Percent predicted FVC remained stable over time in patients with GLILD.
RATIONALE: Granulomatous-lymphocytic interstitial lung disease (GLILD) has emerged as a major cause of morbidity in patients with common variable immunodeficiency (CVID). While GLILD is among the most serious noninfectious pulmonary complications of CVID, risk factors for this condition have not been reported. OBJECTIVES: To identify clinical, physiologic, and serologic risk factors for GLILD in adults with CVID. METHODS: Of 345 consecutive adult patients with CVID, we identified 34 in the National Jewish Health research database who had a radiographic-pathologic diagnosis of GLILD evaluated between 2002 and 2014. Each case was age and sex matched to 52 CVID control subjects. We used logistic regression to determine independent predictors of GLILD. A mixed effects model was used to estimate the longitudinal change in percent predicted FVC. MEASUREMENTS AND MAIN RESULTS: The mean time from CVID diagnosis to GLILD detection was 7.8 years. Compared with matched control subjects, cases were more likely to have a history of autoimmune cytopenia, hypersplenism, polyarthritis, lower marginal zone and switched memory B cells, and restrictive lung function. Multivariate analysis revealed that hypersplenism (odds ratio [OR], 24; 95% confidence interval [CI], 4.5-179.1), polyarthritis (OR, 19; 95% CI, 2.3-206.8), and percent predicted FVC (OR, 0.93; 95% CI, 0.87-0.98) were independently associated with the development of GLILD. The rate of change of percent predicted FVC (slope, P = 0.48) did not vary significantly in patients with GLILD over a mean follow-up of 7 years after diagnosis. CONCLUSIONS:Hypersplenism and polyarthritis are strong risk factors for GLILD in patients with CVID. Percent predicted FVC remained stable over time in patients with GLILD.
Authors: Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: S Jolles; E Carne; M Brouns; T El-Shanawany; P Williams; C Marshall; P Fielding Journal: Clin Exp Immunol Date: 2016-11-28 Impact factor: 4.330
Authors: Leif G Hanitsch; Kirsten Wittke; Anna Barbara Stittrich; Hans Dieter Volk; Carmen Scheibenbogen Journal: J Clin Immunol Date: 2019-10-22 Impact factor: 8.317
Authors: Riccardo Scarpa; Federica Pulvirenti; Antonio Pecoraro; Alessandra Vultaggio; Carolina Marasco; Roberto Ria; Sara Altinier; Nicolò Compagno; Davide Firinu; Mario Plebani; Marco De Carli; Andrea Matucci; Fabrizio Vianello; Angelo Vacca; Giuseppe Spadaro; Isabella Quinti; Carlo Agostini; Cinzia Milito; Francesco Cinetto Journal: Front Immunol Date: 2020-03-31 Impact factor: 7.561
Authors: Jennifer J Meerburg; Ieneke J C Hartmann; Sigune Goldacker; Ulrich Baumann; Annette Uhlmann; Eleni-Rosalina Andrinopoulou; Mariette P C Kemner V/D Corput; Klaus Warnatz; Harm A W M Tiddens Journal: Front Immunol Date: 2020-10-30 Impact factor: 7.561
Authors: Małgorzata Pac; Teresa Bielecka; Katarzyna Grzela; Justyna Komarnicka; Renata Langfort; Sylwia Koltan; Nel Dabrowska-Leonik; Katarzyna Bernat-Sitarz; Maciej Pronicki; Hanna Dmenska; Anna Pituch-Noworolska; Bozena Mikoluc; Barbara Piatosa; Katarzyna Tkaczyk; Ewa Bernatowska; Irena Wojsyk-Banaszak; Katarzyna Krenke Journal: Front Immunol Date: 2020-08-27 Impact factor: 7.561
Authors: David Friedmann; Susanne Unger; Baerbel Keller; Mirzokhid Rakhmanov; Sigune Goldacker; Gernot Zissel; Björn C Frye; Jonas C Schupp; Antje Prasse; Klaus Warnatz Journal: Front Immunol Date: 2021-02-05 Impact factor: 7.561